These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 31592116)

  • 1. Distinct mechanisms of hypoglycaemia in patients with somatostatin-secreting neuroendocrine tumours.
    Wiesli P; Pavlicek V; Brändle M; Pfammatter T; Perren A; Schmid C
    Endocrinol Diabetes Metab; 2019 Oct; 2(4):e00083. PubMed ID: 31592116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolonged life-threatening hypoglycaemia following dose escalation of octreotide LAR in a patient with malignant polysecreting pancreatic neuroendocrine tumour.
    Abell SK; Teng J; Dowling A; Hofman MS; MacIsaac RJ; Sachithanandan N
    Endocrinol Diabetes Metab Case Rep; 2015; 2015():140097. PubMed ID: 25755880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The palliative management of non-islet cell tumour hypoglycaemia with glucocorticoids and somatostatin analogues in an unresectable hepatocellular carcinoma.
    North AS; Thakkar RG; James RA; Hammond JS
    Ann R Coll Surg Engl; 2022 Jun; 104(6):e180-e182. PubMed ID: 35133207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of the somatostatin analogue octreotide to localise and manage somatostatin-producing tumours.
    Angeletti S; Corleto VD; Schillaci O; Marignani M; Annibale B; Moretti A; Silecchia G; Scopinaro F; Basso N; Bordi C; Delle Fave G
    Gut; 1998 Jun; 42(6):792-4. PubMed ID: 9691916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-islet cell tumour-associated hypoglycaemia: 111In-octreotide imaging and efficacy of octreotide, growth hormone and glucocorticosteroids.
    Perros P; Simpson J; Innes JA; Teale JD; McKnight JA
    Clin Endocrinol (Oxf); 1996 Jun; 44(6):727-31. PubMed ID: 8759187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spectrum of malignant somatostatin-producing neuroendocrine tumors.
    Moayedoddin B; Booya F; Wermers RA; Lloyd RV; Rubin J; Thompson GB; Fatourechi V
    Endocr Pract; 2006; 12(4):394-400. PubMed ID: 16901794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Somatostatinomas].
    Pinsard D; Chadenas D
    Diabete Metab; 1988; 14(1):43-59. PubMed ID: 2899036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single photon emission computed tomography procedure improves accuracy of somatostatin receptor scintigraphy in gastro-entero pancreatic tumours.
    Schillaci O; Corleto VD; Annibale B; Scopinaro F; Delle Fave G
    Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S186-9. PubMed ID: 10604127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurofibromatosis associated with somatostatinoma: a report of two patients.
    Swinburn BA; Yeong ML; Lane MR; Nicholson GI; Holdaway IM
    Clin Endocrinol (Oxf); 1988 Apr; 28(4):353-9. PubMed ID: 2903805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A case of insulin and ACTH co-secretion by a neuroendocrine tumour.
    Solomou S; Khan R; Propper D; Berney D; Druce M
    Endocrinol Diabetes Metab Case Rep; 2014; 2014():130082. PubMed ID: 24683485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatostatin analogue treatment of neuroendocrine tumours.
    de Herder WW; van der Lely AJ; Lamberts SW
    Postgrad Med J; 1996 Jul; 72(849):403-8. PubMed ID: 8935599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The octreotide suppression test and [111In-DTPA-D-Phe1]-octreotide scintigraphy in neuroendocrine tumours correlate with responsiveness to somatostatin analogue treatment.
    Shi W; Buchanan KD; Johnston CF; Larkin C; Ong YL; Ferguson R; Laird J
    Clin Endocrinol (Oxf); 1998 Mar; 48(3):303-9. PubMed ID: 9578820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Somatostatinoma: Beyond neurofibromatosis type 1 (Review).
    Sandru F; Carsote M; Valea A; Albu SE; Petca RC; Dumitrascu MC
    Exp Ther Med; 2020 Oct; 20(4):3383-3388. PubMed ID: 32905002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Localization of neuroendocrine tumours and insulinomas using radiolabelled somatostatin analogues, 123I-Tyr3-octreotide and 111In-pentatreotide.
    Ur E; Bomanji J; Mather SJ; Britton KE; Wass JA; Grossman AB; Besser GM
    Clin Endocrinol (Oxf); 1993 May; 38(5):501-6. PubMed ID: 8101146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imaging neuroendocrine tumours with radiolabelled somatostatin analogues and X-ray computed tomography: a comparative study.
    King CM; Reznek RH; Bomanji J; Ur E; Britton KE; Grossman AB; Besser GM
    Clin Radiol; 1993 Dec; 48(6):386-91. PubMed ID: 8293643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues.
    Kaltsas GA; Papadogias D; Makras P; Grossman AB
    Endocr Relat Cancer; 2005 Dec; 12(4):683-99. PubMed ID: 16322317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Octreotide scintigraphy localizes somatostatin receptor-positive islet cell carcinomas.
    Becker W; Marienhagen J; Scheubel R; Saptogino A; Bakker WH; Breeman WA; Wolf F
    Eur J Nucl Med; 1991; 18(11):924-7. PubMed ID: 1684323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy of somatostatin analogues in the treatment of neuroendocrine tumours based on the results of recent clinical trials].
    Igaz P
    Orv Hetil; 2014 Nov; 155(48):1908-12. PubMed ID: 25417137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Localisation of neuroendocrine tumours of the upper gastrointestinal tract.
    Zimmer T; Ziegler K; Bäder M; Fett U; Hamm B; Riecken EO; Wiedenmann B
    Gut; 1994 Apr; 35(4):471-5. PubMed ID: 8174983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FNAC diagnosis of pancreatic somatostatinoma.
    Dinesh U; Pervatikar SK; Rao R
    J Cytol; 2009 Oct; 26(4):153-5. PubMed ID: 21938182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.